Navigation Links
Collegium Pharmaceutical's CEO to Present at the Cowen & Company 33rd Annual Health Care Conference in Boston on March 6, 2013
Date:2/28/2013

CANTON, Mass., Feb. 28, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the company's President and CEO, Michael Heffernan , will present the company's corporate overview on Wednesday, March 6, 2013 at 11:00 am EST at the Cowen & Company 33rd Annual Health Care Conference. The conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts.

The Company's lead development program is Oxycodone DETERx® (COL-003), a tamper-resistant, extended-release oxycodone product utilizing its proprietary DETERx® technology. The Oxycodone DETERx® formulation was specifically designed to provide and preserve extended release of the active ingredient following the most common methods of product tampering employed by drug abusers (e.g., crushing, chewing, heating for IV injection, etc.). The product is currently in the final stage of clinical development and has been designated Fast Track Status by the FDA due to its potential to address the problem of prescription drug abuse, a major public health issue in the U.S.

About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides extended release delivery, unique tamper-resistant properties, and flexible dose administration options. For more information, visit the Company's website at www.collegiumpharma.com.

Contact:

Michael Heffernan , President
Collegium Pharmaceutical, Inc.
781-713-3699

SOURCE Collegium Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Collegium Pharmaceutical to Present at Piper Jaffrays 24th Annual Healthcare Conference
2. Collegium Pharmaceutical Announces Relocation to Massachusetts
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
6. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
7. Icahn Issues Statement Regarding Amylin Pharmaceuticals
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
11. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... August 31, 2015 A ... global cardiovascular monitoring and diagnostic devices market stood ... to reach a value of approximately US$7.0 billion ... between 2013 and 2019. The title of the ... (ECG, Holter Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, ...
(Date:8/31/2015)... 31, 2015  Regulatory affairs professionals work at ... are often strict and legislation is ever-changing. The ... for professionals who have a deep understanding of ... product lifecycle and demonstrate its use across various ... California, Irvine Extension , in partnership with the ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , Aug. ... ; EURONEXT: SAN) and the life sciences team at ... care and outcomes for people with type 1 and ... treatments and devices with Google,s expertise in analytics, miniaturized ... explore how to improve diabetes care by developing new ...
Breaking Medicine Technology:Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6
... UCB) and U.S. based partner Immunomedics Inc. (Nasdaq: ... IIb study, EMBLEM™, showed that certain doses of epratuzumab ... in disease activity in adult patients with moderate to ... designed to evaluate the efficacy and safety of epratuzumab ...
... innovator of Packaging Execution Systems (PES) for the pharmaceutical ... engineering, automation and manufacturing optimization services company, today announced ... Service Provider (SSP). VCG will now sell, install and ... United States. The SSP program is ...
Cached Medicine Technology:Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 2Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 3Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 4Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 5Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 6Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 7Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements 2Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements 3
(Date:8/31/2015)... ... ... MeYou Health ®, a social well-being company and wholly owned subsidiary ... including an in-app step tracker. , Walkadoo is a pedometer-based walking program ... broadly assign every Walkadoo member 10,000 steps a day (as is typical for many ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s big news for ZendyHealth ... healthcare industry. , Consumer driven health plans (CDHPs) are a growing phenomenon, and ... strategic role to the company, and another to answer customers’ questions directly. , John ...
(Date:8/31/2015)... ... 31, 2015 , ... The Brooks Group, a global sales ... department devoted to helping organizations identify and keep the best talent both inside ... Brooks Group believes in offering a solution that goes beyond simply providing assessments ...
(Date:8/31/2015)... ... August 31, 2015 , ... Now here’s some good health news: Nearly two-thirds ... half your grains whole,” with the majority of Americans eating more whole grains than ... (WGC) released these findings and others from the 2015 Whole Grains Consumer Insights ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... ACTION. NOT CHANCES. (SM) will be featured on a digital screen projected above ... is designed to inspire and promote earlier awareness of the symptoms of ovarian ...
Breaking Medicine News(10 mins):Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3
... impact of a job burn out. Apart from it affecting ... host of ailments, say Scientists. //This study supports the various ... contribute to high blood pressure, metabolic syndrome, flu, and heart ... revealed that risk of Type 2 Diabetes was almost 1.8 ...
... Polio Eradication Initiatives and now in an effort to ... planned to immunize 22 million children in Bangladesh under ... Bangladesh will carry out the initiatives along with the ... and the U.S. Centers for Disease Control and Prevention ...
... Health of the Kingdom of Saudi Arabia have taken a ... regardless //of age and vaccination status should receive at least ... Saudi Arabia. This decision was conveyed to the Ministry of ... November 21, 2006. ,The Ministry of Health & ...
... last winter and the number is expected to be greater this ... due to an acute shortage in the availability of the vaccine ... jab. The Department of Health had ordered for 15.2 million doses ... far. Researchers warn that those who do not get vaccinated by ...
... Institute of Vaccines and Biological Products, has announced that ... H5N1 vaccine for// humans from chick embryos. ... and cockerels and similar reactions were observed.The observations have ... Vaccines and Biological Products. Its reported that the quality ...
... increasing use of contaminated drug syringes are the main reasons for ... major cities like// Delhi, Mumbai and Chennai, states a new study. ... of men who have sex with men. In Bangalore, for example, ... know how the virus is transmitted, and a large proportion of ...
Cached Medicine News:Health News:Flu Vaccine Shortage In Britain Causes Anxiety 2Health News:Homosexuality, drug abuse increasing HIV in India: study 2
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
... The Shandon Finesse ME+ is designed ... in todays busy laboratories by being one ... microtomes offered today. Excellent for routine wax ... Finesse ME + provides high quality sections ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: